Loading…

Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis

Killed whole-cell oral cholera vaccines (kOCVs) are becoming a standard cholera control and prevention tool. However, vaccine efficacy and direct effectiveness estimates have varied, with differences in study design, location, follow-up duration, and vaccine composition posing challenges for public...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2017-10, Vol.17 (10), p.1080-1088
Main Authors: Bi, Qifang, Ferreras, Eva, Pezzoli, Lorenzo, Legros, Dominique, Ivers, Louise C, Date, Kashmira, Qadri, Firdausi, Digilio, Laura, Sack, David A, Ali, Mohammad, Lessler, Justin, Luquero, Francisco J, Azman, Andrew S, Cavailler, Philippe, Sreenivasan, Nandini, Matzger, Helen, Luquero, Francisco, Grais, Rebecca, Wiesner, Lale, Ko, Melissa, Rouzier, Vanessa, Peak, Corey, Landegger, Justine, Lynch, Julia, Azman, Andrew, Sack, David, Henkens, Myriam, Ciglenecki, Iza, Ivers, Louise, Diggle, Emma, Weiss, Mitchell, Hinman, Alan, Maina, Kahindo, Mirza, Imran, Gimeno, Guillermo, Levine, Myron
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Killed whole-cell oral cholera vaccines (kOCVs) are becoming a standard cholera control and prevention tool. However, vaccine efficacy and direct effectiveness estimates have varied, with differences in study design, location, follow-up duration, and vaccine composition posing challenges for public health decision making. We did a systematic review and meta-analysis to generate average estimates of kOCV efficacy and direct effectiveness from the available literature. For this systematic review and meta-analysis, we searched PubMed, Embase, Scopus, and the Cochrane Review Library on July 9, 2016, and ISI Web of Science on July 11, 2016, for randomised controlled trials and observational studies that reported estimates of direct protection against medically attended confirmed cholera conferred by kOCVs. We included studies published on any date in English, Spanish, French, or Chinese. We extracted from the published reports the primary efficacy and effectiveness estimates from each study and also estimates according to number of vaccine doses, duration, and age group. The main study outcome was average efficacy and direct effectiveness of two kOCV doses, which we estimated with random-effect models. This study is registered with PROSPERO, number CRD42016048232. Seven trials (with 695 patients with cholera) and six observational studies (217 patients with cholera) met the inclusion criteria, with an average two-dose efficacy of 58% (95% CI 42–69, I2=58%) and effectiveness of 76% (62–85, I2=0). Average two-dose efficacy in children younger than 5 years (30% [95% CI 15–42], I2=0%) was lower than in those 5 years or older (64% [58–70], I2=0%; p
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(17)30359-6